[Hypoxia in cancer malignity. Review]

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Context:

• Solid tumors frequently exhibit hypoxia, a condition that drives tumor progression and resistance to therapies like radiotherapy and chemotherapy.
• Hypoxia-Inducible Factor-1 (HIF-1) is a key transcription factor that regulates cellular adaptation to low-oxygen environments within tumors.
• HIF-1 activation influences critical cancer hallmarks including proliferation, altered glucose metabolism, acidosis, angiogenesis, and metastasis.

Purpose:

• To review the multifaceted role of HIF-1 in mediating tumor cell adaptation to hypoxic stress.
• To elucidate the implications of HIF-1 activity in promoting tumor angiogenesis and metastasis.
• To highlight the therapeutic potential of targeting HIF-1 pathways in cancer treatment.

Summary:

• Hypoxia is prevalent in solid tumors, contributing to progression and therapeutic failure.
• HIF-1 is the master regulator of cellular response to hypoxia, orchestrating survival mechanisms.
• HIF-1 target genes are implicated in proliferation, metabolism, angiogenesis, and metastasis.

Impact:

• Enhanced understanding of HIF-1's role in cancer progression and treatment resistance.
• Provides a foundation for developing novel anti-cancer strategies targeting the HIF-1 pathway.
• Potential for improved therapeutic outcomes by inhibiting HIF-1-driven tumor growth and spread.